| Recurrence | Death without recurrence | Death after recurrence | ||||
---|---|---|---|---|---|---|---|
TR | 95% CI | TR | 95% CI | TR | 95% CI | ||
Age at Diagnosis (years) | Trend effect | 0.764 | 0.538–0.935* | 0.396 | 0.313–0.532 * | 0.659 | 0.559–0803 * |
Gender | Male | 0.596 | 0.456–0.855 * | 0.666 | 0.363–1.074 | 0.951 | 0.697–1.203 |
Metastasis to other sites | Yes | 0.735 | 0.589–1.022 | 0.566 | 0.490–0.835* | 0.821 | 0.594–1.052 |
Number of chemotherapies | Trend effect | 1.583 | 1.367–1.863 * | 1.541 | 1.332–2.243 * | 2.029 | 1.792–2.191 * |
Grade (differentiation level) | Well | Referent | --- | --- | --- | --- | --- |
Moderate | 0.648 | 0.503–0.955 * | 0.527 | 0.387–0.674 * | 1.053 | 0.839–1.277 | |
Poor | 0.856 | 0.733–0.988 * | 0.558 | 0.380–1.030 | 1.310 | 0.875–1.174 | |
Tumor size | Trend effect | 0.709 | 0.610–0.929 * | 0.595 | 0.500–0.679 * | 0.893 | 0.781–1.010 |
PT-Stage | T2 | Referent | --- | --- | --- | --- | --- |
T3 | 0.601 | 0.530–0.713 * | 0.363 | 0.592 − 0.301 * | 0.983 | 0.746–1.414 | |
T4 | 0.962 | 0.872–1.319 | 0.434 | 0.347–0.545* | 0.853 | 0.509–1.402 | |
TX | NC | NC | NC | NC | NC | NC | |
PN-Stage | N0 | Referent | --- | --- | --- | --- | --- |
N1 | 1.272 | 0.967–1.586 | 1.947 | 1.728–2.122 | 0.760 | 0.576–1.468 | |
N2 | 0.714 | 0.577–0.935 * | 1.302 | 1.000–1.620 | 0.802 | 0.592 − 0.086 | |
NX | NC | NC | NC | NC | NC | NC |